| Golden, Jeffrey |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 128 | US | Ifetroban Sodium, ifetroban, Placebo | Cumberland Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
| Perlman, Susan |
| Recruiting | 3 | 106 | Europe, US | Dexamethasone sodium phosphate, DSP, Placebo | Quince Therapeutics S.p.A., Biotrial | Ataxia Telangiectasia | 08/25 | 09/25 | | |
| Recruiting | 3 | 106 | Europe, US | Dexamethasone sodium phosphate | Quince Therapeutics S.p.A., Biotrial | Ataxia Telangiectasia | 11/26 | 11/26 | | |
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia |
|
|
| Terminated | 2/3 | 23 | Europe, US, RoW | SLS-005, Placebo | Seelos Therapeutics, Inc. | Spinocerebellar Ataxia Type 3 | 11/23 | 11/23 | | |
| Recruiting | 2 | 39 | Europe, US | IB1001, N-Acetyl-L-Leucine | IntraBio Inc | Ataxia Telangiectasia, Louis Bar Syndrome | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 159 | Europe, Japan, US | TAK-341, MEDI1341, Placebo | Takeda, AstraZeneca | Multiple System Atrophy | 07/25 | 07/25 | | |
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy |
|
|
| Recruiting | 2 | 80 | US | ONO-2808, Placebo | Ono Pharmaceutical Co. Ltd | Multiple System Atrophy (MSA) | 08/25 | 08/25 | | |
| Completed | N/A | 128 | US | | University of Chicago, Pfizer, Biogen, APDM Wearable Technologies | Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia | 04/24 | 06/24 | | |
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it for the First Time |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | Omaveloxolone, SKYCLARYS, BIIB141 | Reata, a wholly owned subsidiary of Biogen | Friedreich Ataxia | 10/29 | 10/29 | | |
| Geschwind, Michael |
| Recruiting | 1/2 | 37 | US | intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery | UniQure Biopharma B.V. | Huntington's Disease | 04/29 | 06/29 | | |
|
|
|
| Arean, Patricia A |
NCT04507360: Enhancing Engagement With Digital Mental Health Care |
|
|
| Active, not recruiting | N/A | 570 | US | Study 1, Generic Response, Study 1, Tailored Response, Study 1, Generic Resources, Study 1, Tailored Resources by Desired Resources, Study 1, Embedded single-question DIY, Study 1, Embedded full DIY within content page, Study 1, Single question plus full DIY, Study 1, Content-as-usual, Study 2, Control, Study 2, DIY tool without AI, Study 2, DIY tool with AI, Study 1, Tailored Resources by Demographics | University of Washington, Mental Health America, Talkspace, National Institute of Mental Health (NIMH) | Engagement, Patient | 08/24 | 11/24 | | |
| Rosenthal, Philip |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). |
|
|
| Completed | 2 | 27 | Europe, US, RoW | Maralixibat, Formerly LUM001 and SHP625 | Mirum Pharmaceuticals, Inc. | Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease | 12/24 | 12/24 | | |
| Gitelman, Stephen |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
| Shaffrey, Christopher |
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity |
|
|
| Recruiting | N/A | 100 | US | Symphony OCT System | International Spine Study Group Foundation, DePuy Synthes | Cervical Deformity | 07/27 | 07/27 | | |
| Recruiting | N/A | 500 | Canada, US | Index or spine revision surgery for complex adult spinal deformity | International Spine Study Group Foundation, Medtronic, Globus Medical Inc, SI-BONE, Inc. | Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance | 12/31 | 07/32 | | |
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0 |
|
|
| Recruiting | N/A | 200 | US | Surgical intervention | International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc. | Cervical Deformity | 12/32 | 07/33 | | |
NCT04888104: Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients |
|
|
| Recruiting | N/A | 225 | US | Index or revision spine surgery for complex adult spinal deformity, VersaTie System | International Spine Study Group Foundation, NuVasive | Adult Spinal Deformity, Scoliosis, Kyphosis | 12/34 | 12/34 | | |
| Daud, Adil |
| Active, not recruiting | 2 | 77 | Europe, Canada, US | SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin | Seagen Inc., Merck Sharp & Dohme LLC | Melanoma, Carcinoma, Non-Small- Cell Lung | 01/24 | 10/25 | | |
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection |
|
|
| Terminated | 2 | 7 | US | Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay | Washington University School of Medicine, Genentech, Inc. | Stage II Melanoma | 11/23 | 11/23 | | |
| Completed | 1/2 | 29 | Europe, US | ANV419, Pembrolizumab, Ipilimumab | Anaveon AG, Anaveon AG | Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma | 08/24 | 08/24 | | |
| Recruiting | 1 | 275 | Europe, Canada, US | PF-08046049 | Seagen Inc. | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 11/26 | 11/27 | | |
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy |
|
|
| Active, not recruiting | 1 | 6 | US | XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104 | University of California, San Francisco, Xencor, Inc. | Metastatic Melanoma, Advanced Melanoma | 12/25 | 12/25 | | |
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma |
|
|
| Recruiting | N/A | 25 | US | Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection | University of California, San Francisco, Merck Sharp & Dohme LLC | Melanoma, Advanced Melanoma | 08/26 | 08/26 | | |
| Fong, Lawrence |
| Completed | 2 | 23 | US | Atezolizumab, MPDL3280A | Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation | Carcinoma, Transitional Cell | 03/23 | 03/23 | | |
NCT03248570: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects |
|
|
| Completed | 2 | 26 | US | Pembrolizumab, KEYTRUDA, MK-3475, Chemotherapy | University of California, San Francisco, Merck Sharp & Dohme LLC, National Cancer Institute (NCI) | Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | 09/23 | 09/23 | | |
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition |
|
|
| Withdrawn | 2 | 48 | US | Vactosertib(TEW-7197)/ Durvalumab | MedPacto, Inc., AstraZeneca | Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma | 12/23 | 12/24 | | |
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT |
|
|
| Active, not recruiting | 2 | 23 | US | Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT | David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc. | Prostatic Neoplasms | 08/25 | 08/25 | | |
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 2 | 68 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928 | David Oh, Genentech, Inc. | Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer | 02/25 | 02/25 | | |
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors |
|
|
| Completed | 1 | 26 | Europe, US | VB10.NEO, Atezolizumab, Tecentriq | Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS | Solid Tumors, Adult | 10/24 | 10/24 | | |
| Link, Thomas M |
EMBOLISE, NCT04402632: Embolization of the Middle Meningeal Artery with ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma |
|
|
| Active, not recruiting | N/A | 600 | US | Surgical Management, Surgical Management + Treatment, No Treatment, Treatment | Medtronic Neurovascular Clinical Affairs | Subdural Hematoma | 12/24 | 03/25 | | |
| Alvarez, Edwin |
| Recruiting | 1/2 | 148 | US | Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio | Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company | Endometrial Cancer | 10/25 | 10/26 | | |
| Recruiting | 1 | 90 | US | NKT3447 | NiKang Therapeutics, Inc. | Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer | 03/25 | 05/25 | | |
| Bess, Shay |
PON, NCT00738439: Prospective, Multi-Center Adult Spinal Deformity Outcomes Database Registry |
|
|
| Active, not recruiting | N/A | 1999 | US | | Shay Bess, DePuy Spine, K2M, Inc., NuVasive, Zimmer Biomet, Orthofix Inc. | Spinal Deformity | 12/24 | 09/25 | | |
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity |
|
|
| Recruiting | N/A | 100 | US | Symphony OCT System | International Spine Study Group Foundation, DePuy Synthes | Cervical Deformity | 07/27 | 07/27 | | |
| Recruiting | N/A | 500 | Canada, US | Index or spine revision surgery for complex adult spinal deformity | International Spine Study Group Foundation, Medtronic, Globus Medical Inc, SI-BONE, Inc. | Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance | 12/31 | 07/32 | | |
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0 |
|
|
| Recruiting | N/A | 200 | US | Surgical intervention | International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc. | Cervical Deformity | 12/32 | 07/33 | | |
NCT04888104: Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients |
|
|
| Recruiting | N/A | 225 | US | Index or revision spine surgery for complex adult spinal deformity, VersaTie System | International Spine Study Group Foundation, NuVasive | Adult Spinal Deformity, Scoliosis, Kyphosis | 12/34 | 12/34 | | |
| Smith, Justin |
NCT01588054: Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity |
|
|
| Completed | N/A | 100 | US | | International Spine Study Group Foundation, DePuy Spine | Cervical Deformity, Kyphosis, Scoliosis | 05/21 | 06/21 | | |
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity |
|
|
| Recruiting | N/A | 100 | US | Symphony OCT System | International Spine Study Group Foundation, DePuy Synthes | Cervical Deformity | 07/27 | 07/27 | | |
| Recruiting | N/A | 500 | Canada, US | Index or spine revision surgery for complex adult spinal deformity | International Spine Study Group Foundation, Medtronic, Globus Medical Inc, SI-BONE, Inc. | Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance | 12/31 | 07/32 | | |
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0 |
|
|
| Recruiting | N/A | 200 | US | Surgical intervention | International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc. | Cervical Deformity | 12/32 | 07/33 | | |
NCT04888104: Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients |
|
|
| Recruiting | N/A | 225 | US | Index or revision spine surgery for complex adult spinal deformity, VersaTie System | International Spine Study Group Foundation, NuVasive | Adult Spinal Deformity, Scoliosis, Kyphosis | 12/34 | 12/34 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 470 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
